RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty

Model scores of the 29,894 trials active now.

Model score 22% for any early termination, 9% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (493 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-10-25. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: paclitaxelpatienttreating000lesion
  Phrases that lowered it: singleindexevaluate theto evaluatesafety
• Sponsor's past termination rate: 16.3% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Minimum age: 20 (lowers risk) · Who can join
• Has a data monitoring committee: Yes (raises risk) · Design
• Phase: 3 (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 34 (lowers risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 22.9% (raises risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 95.2% (raises risk) · Drug's FDA history
• Blinding: single (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Sponsor's past trials: 178 (lowers risk) · Sponsor's track record
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Disease area, cancer: No (lowers risk) · Disease area
• Number of arms: 2 (raises risk) · Design
• Keywords listed: 7 (lowers risk) · Design
• Drug's FAERS reports before start: 30057 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization NCT03942601 · started 2019 · scored riskier than 64% of active trials terminated
• Safety/Feasibility of Vonapanitase Following Angioplasty for Patients With Peripheral Artery Disease (PAD) Below the Knee (BTK) NCT02956993 · started 2016 · scored riskier than 47% of active trials completed
• Study of PVS-10200 for the Treatment of Restenosis in Patients With Peripheral Artery Disease (TRIUMPH) NCT01099215 · started 2010 · scored riskier than 77% of active trials completed
• Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities NCT02217501 · started 2015 · scored riskier than 77% of active trials completed
• Pilot Study of PRT-201 Following Angioplasty in Patients With Peripheral Artery Disease (PAD) NCT01616290 · started 2012 · scored riskier than 67% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.